A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Proteinuric Kidney Disease

Interventions

DRUG: MZE829

Sponsor

Maze Therapeutics